imatinib mesylate has been researched along with Lassitude in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| den Hollander, D; Desar, IME; Dirkson, AR; Gelderblom, H; Husson, O; Kraaij, W; Oosten, A; Reyners, AKL; Steeghs, N; van der Graaf, WTA; van Oortmerssen, G; Verberne, S | 1 |
| Doki, Y; Eguchi, H; Hayashi, Y; Hirota, S; Koh, M; Kurokawa, Y; Makino, T; Motoori, M; Nakajima, K; Nishida, T; Nishigaki, T; Omori, T; Saito, T; Takahashi, T; Takehara, T; Tanaka, K; Teranishi, R; Yamamoto, K; Yamashita, K | 1 |
| Chen, S; Cheng, F; Gale, RP; Guo, H; Li, Q; Li, W; Qu, J; Xiang, H; Zhang, Y | 1 |
| Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y | 1 |
| Begna, K; Smith, CJ; Stewart, G | 1 |
| Bhargava, S; Kumar, M; Malhotra, B; Malhotra, H; Rathore, OS; Sharma, P | 1 |
| Atallah, E; O'Dwyer, M | 1 |
| Akard, L; Albitar, M; Burke, JM; Cortes, JE; Giles, FJ; Goldberg, SL; Kantarjian, HM; Kerr, R; McDougall, K; Powell, BL; Radich, J; Saleh, M; Salvado, A; Wetzler, M | 1 |
| Hara, K; Hijioka, S; Kawai, H; Kondo, S; Matsumoto, K; Mizuno, N; Niwa, Y; Sawaki, A; Tajika, M; Yamao, K | 1 |
| Fu, D; Jin, C; Ni, Q; Yang, F | 1 |
| Baccarani, M; Breccia, M; Caocci, G; Cardoni, A; Chie, W; Cocks, K; Efficace, F; Kossak-Roth, U; Mandelli, F; Naeem, A; Nicolatou-Galitis, O; Saussele, S; Sprangers, M; Vignetti, M | 1 |
| Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Cottone, F; Efficace, F; Gherlinzoni, F; Iurlo, A; Mandelli, F; Pardini, S; Rossi, AR; Rosti, G; Salvucci, M; Tiribelli, M; Vignetti, M | 1 |
| Abraham, I; MacDonald, K | 1 |
| Arias-Pulido, H; Bauman, JE; Carr, LL; Cerilli, LA; Eaton, KD; Jones, DV; Lee, SJ; Martins, RG; Wallace, SG | 1 |
| Jacobsen, PB; Jim, HS; Komrokji, R; Lancet, J; Lee, MR; Phillips, KM; Pinilla-Ibarz, J; Small, BJ; Sokol, L; Sotomayor, E; Sweet, K; Tinsley, S | 1 |
| Antin, JH | 1 |
| Azzoli, CG; Crapanzano, JP; Dunne, M; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Rizvi, N; Tyson, L | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Ladie, N; Murgo, A; O'Brien, S; Quintás-Cardama, A; Verstovsek, S | 1 |
| Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y | 1 |
1 review(s) available for imatinib mesylate and Lassitude
| Article | Year |
|---|---|
Extra-gastrointestinal stromal tumor of the pancreas: clinical characteristics, diagnosis, treatment, and outcome.
Topics: Abdominal Pain; Antineoplastic Agents; Benzamides; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Piperazines; Pyrimidines; Splenectomy; Weight Loss | 2011 |
7 trial(s) available for imatinib mesylate and Lassitude
| Article | Year |
|---|---|
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Dasatinib; Diarrhea; DNA Copy Number Variations; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Stromal Tumors; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neutropenia; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Proteinuria; Sunitinib | 2020 |
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2009 |
Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Imatinib Mesylate; Indoles; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Portography; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2011 |
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Frail Elderly; Humans; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Signal Transduction; Survival Analysis; Treatment Outcome | 2012 |
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Edema; Fatigue; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Failure | 2005 |
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Benzamides; Blast Crisis; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Treatment Outcome | 2007 |
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting | 2007 |
11 other study(ies) available for imatinib mesylate and Lassitude
| Article | Year |
|---|---|
Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.
Topics: Cross-Sectional Studies; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Muscle Cramp; Protein Kinase Inhibitors; Quality of Life; Surveys and Questionnaires | 2022 |
Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
Topics: Antineoplastic Agents; Drug Monitoring; East Asian People; Edema; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Retrospective Studies; Treatment Outcome | 2023 |
SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.
Topics: Aged; COVID-19; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; SARS-CoV-2 | 2023 |
44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis.
Topics: Adult; Basophils; Diagnosis, Differential; Exercise Tolerance; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Male; Protein Kinase Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Diarrhea; Fatigue; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Nausea; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2014 |
Practical considerations for the management of patients in the tyrosine kinase inhibitor era.
Topics: Antineoplastic Agents; Benzamides; Exanthema; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Muscular Diseases; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anxiety; Benzamides; Edema; Europe; Fatigue; Female; Health Personnel; Humans; Imatinib Mesylate; Iraq; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Muscle Cramp; Patients; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Social Support; Surveys and Questionnaires; Taiwan; Young Adult | 2012 |
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Benzamides; Fatigue; Female; Humans; Imatinib Mesylate; Information Seeking Behavior; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Piperazines; Pyrimidines; Quality of Life; Risk Factors; Social Support; Treatment Outcome | 2012 |
Why are patients with chronic myeloid leukaemia (non-)adherent?
Topics: Antineoplastic Agents; Benzamides; Fatigue; Female; Humans; Imatinib Mesylate; Information Seeking Behavior; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Piperazines; Pyrimidines; Quality of Life; Social Support | 2012 |
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Dasatinib; Depression; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States; Young Adult | 2013 |
A 41-year-old woman with chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Decision Making; Fatigue; Female; Headache; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Stem Cell Transplantation | 2003 |